Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Statistics in Medicine|October 16, 1999
Instrumental variables when evaluating screening trials: estimating the benefit of detecting cancer by screeningM W McIntoshStatistics in Medicine|August 30, 1996
The population risk as an explanatory variable in research synthesis of clinical trialsM W McIntoshStatistics in Medicine|October 20, 1998
An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trialsC H Schmid, J Lau, M W McIntosh, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 25, 2000
Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screeningC Crump, M W McIntosh, N Urban, et al.Gynecologic Oncology|September 24, 2004
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaM W McIntosh, C Drescher, B Karlan, et al.American Journal of Preventive Medicine|August 3, 1999
Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use?K L Edlefsen, M T Mandelson, M W McIntosh, et al.Journal of Clinical Epidemiology|April 1, 1997
Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatmentD R Zucker, C H Schmid, M W McIntosh, et al.Pageof 1